Mahmoud Mohammadi

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 4

Top Topics

Renal Cell Carcinoma

Patient Reported Outcomes

Ejection Fraction

Acute Lymphoblastic Leukemia

Top Venues

Targeted oncology

Expert opinion on investigational drugs

This page only lists publications with an associated author ORCID identifier.

Publications

Mahmoud Mohammadi, Nikki S IJzerman, Dide den Hollander, Roos F Bleckman, Astrid W Oosten, Ingrid M E Desar, An K L Reyners, Neeltje Steeghs, Hans Gelderblom
Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data. Targeted oncology (2023)
Mahmoud Mohammadi, Thekla M Jansen-Werkhoven, Nikki S Ijzerman, Dide den Hollander, Roos F Bleckman, Astrid W Oosten, Ingrid M E Desar, An K L Reyners, Neeltje Steeghs, Hans Gelderblom
Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients. Targeted oncology 17 (6) (2022)
Mahmoud Mohammadi, André B P van Kuilenburg
Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Expert opinion on investigational drugs 30 (2) (2020)
Nikki S IJzerman, Cas Drabbe, Dide den Hollander, Mahmoud Mohammadi, Hester van Boven, Ingrid M E Desar, André B P van Kuilenburg, Dirk J Grünhagen, An K L Reyners, Max M Van Noesel, Ron H J Mathijssen, Neeltje Steeghs, Winette T A van der Graaf
Gastrointestinal Stromal Tumours (GIST) in Young Adult (18-40 Years) Patients: A Report from the Dutch GIST Registry. Cancers 12 (3) (2020)